Diabetic kidney disease has a troubling profile: it is the leading cause of kidney failure in the Western world, affects 12+ million Americans, and has no cure. New drugs (SGLT2 inhibitors, GLP-1 agonists) delay the collapse but do not stop it. Now, a team of researchers from the Mayo Clinic offers a revolutionary approach: treating the zombie cells that cause inflammation in the kidneys. Results published in eBioMedicine (Lancet) in March 2026 show that a combination of Dasatinib + Quercetin (D+Q) removes zombie cells, reduces inflammation, and improves kidney function. This is a new horizon for treating a disease with no cure.
Why Do Diabetic Kidneys Develop?
In uncontrolled diabetes, high glucose levels cause chronic damage to the small blood vessels in the kidneys. Over time:
- Reduced filtration: Kidneys do not clean blood effectively
- Protein leaks into urine (proteinuria): First sign
- Accumulation of waste: Toxins remain in the blood
- Ultimately: kidney failure: Need for dialysis or transplant
Existing treatments help but do not solve the problem. In 25-40% of patients, progression to kidney failure occurs anyway.
The Connection to Cellular Senescence
The team investigated the link between diabetes and zombie cells. They found that in the kidneys of diabetic patients, there is an accumulation of senescent cells:
- In tubular epithelial cells
- In nephrons (filtration units)
- In kidney blood vessels
- Even in smooth muscle cells around blood vessels
These zombie cells secrete SASP (Senescence-Associated Secretory Phenotype): pro-inflammatory cytokines, abnormal growth factors, and proteases that disrupt the environment. This creates a destructive cycle: inflammation → more damage → more zombie cells → more inflammation.
The Intervention: Dasatinib + Quercetin
Dasatinib (Sprycel) is a standard drug for types of leukemia (CML, ALL). It inhibits kinases and activates cell death specifically in cells that rely on certain anti-apoptotic pathways.
Quercetin is a natural flavonoid found in onions, apples, berries, and green tea. At high concentrations, it also activates cell death.
The D+Q combination was developed in 2015 by Mayo Clinic researchers and served as the first senolytic. The two together act on different pathways and are more effective than either alone.
The Experiment: In Diabetic Mice
The team created diabetic mice (a standard model of diabetic kidney disease). Half received D+Q once every two weeks, half received a placebo. After 8 weeks:
- Zombie cells in the kidney decreased by 50-60%
- Kidney inflammation significantly reduced (lower blood markers CRP, IL-6)
- Kidney filtration improved (higher GFR)
- Protein in urine decreased (less damage to filters)
- "Gerontoprotective factors" increased (Klotho, sirtuins)
In short: the kidneys aged less, lived better.
Repeating the Experiment in Human Cells
The team also tested if this works in cultured human kidney cells. They took cells from:
- Patients with diabetes and kidney disease
- Healthy individuals
Added D+Q. Old senescent cells died (even 70% of them). Healthy cells survived. Excellent selectivity.
The Clinical Trial: Beginning
Following these results, the team at the Mayo Clinic conducted a small pilot trial in humans:
- 9 patients with diabetes and advanced kidney disease
- Received D+Q for a short period
- Biopsies were performed before and after
Results:
- Zombie cells in skin and fat decreased
- Mild side effects (headaches, intestinal discomfort) resolved after days
- No dangerous effects
This was a small, pilot trial. But it proved safety in humans. Larger trials are now planned.
Why D+Q and Not Another Regular Drug?
The team explains the advantages:
1. Mechanistic Proof
Zombie cells are the proven cause of inflammation in diabetic kidneys. Removing them addresses the root of the problem, not just symptoms.
2. Available Drugs
Both drugs are FDA-approved. Dasatinib for cancer, Quercetin as a supplement. Requires approval for a new indication but not a new drug.
3. Synergistic Combination
The two together are more effective than the sum of their parts. Dasatinib kills certain types of zombie cells. Quercetin kills other types. Together - more.
4. Short-Term Use
Unlike most diabetes drugs that need to be taken daily, senolytics are given only occasionally (once every two weeks to a month). More convenient, fewer cumulative side effects.
Who Is This Relevant For?
If clinical trials succeed, groups that could benefit:
- Type 2 diabetes patients with early microalbuminuria: Early intervention
- Diabetics with declining eGFR: Halting progression
- People with non-diabetic CKD (chronic kidney disease): May also work for them
- Patients after kidney failure undergoing transplant: To prevent rejection (zombie cells contribute to rejection)
Systemic Implications
If D+Q receives FDA approval for the indication of diabetic kidney disease:
- Enormous savings for healthcare systems: Dialysis costs $80,000+ per year per patient
- Improved quality of life: Patients with kidney failure suffer greatly
- Opening the general senolytic field: Approval for one indication = proof for others
When in the Clinic?
Larger clinical trials are planned for 2026-2028. FDA approval for this indication may come in 2029-2030. Until then:
Why Not Take D+Q Yourself?
Dasatinib is a prescription drug with significant side effects (risk of heart and lung problems). It is not to be taken without a doctor. Quercetin as a supplement is interesting, but in senolytic amounts it requires a high dose (1,000+ mg per day).
What Can Be Done Now?
If you have diabetes and want to prevent kidney disease:
- Blood sugar control is first: HbA1c below 7%
- Treatment with an SGLT2 inhibitor: empagliflozin, dapagliflozin - protect kidneys
- GLP-1 agonist: semaglutide - also protective
- Blood pressure control: below 130/80
- Mediterranean diet: reduces systemic inflammation
- Regular physical activity: naturally removes zombie cells
- Quercetin as a supplement: 500 mg/day is safe, though the senolytic effect is uncertain
The Bottom Line
Diabetic kidney disease was a death sentence. Now, with a new understanding of zombie cells as a cause of the disease, there is a new direction. Dasatinib + Quercetin is the first drug of this approach, and there is a high likelihood it will remain. If you have diabetes and your kidneys are starting to show signs of trouble, ask your doctor about clinical trial conditions. By 2030, you may be able to break the progression to kidney failure entirely.
💬 תגובות (0)
היו הראשונים להגיב על המאמר.